as an initial investigation to determine whether opioid peptides contribute to any of the clinical manifestations of hepatic disease nalmefene , a specific opioid antagonist devoid of agonist activity , was given to 11 patients with cirrhosis .
C0023895
hepatic disease
C0023890
cirrhosis